Trial Profile
Single Arm, Single Dose Clinical Study to Investigate Efficacy of Treat-and-Extend Regimen of Intravitreal Aflibercept Injection in Diabetic Macular Edema
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms VIBIM
- 27 Feb 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 27 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2019.
- 27 Feb 2019 Status changed from recruiting to active, no longer recruiting.